Apixaban Dosing in Patients With Kidney Failure Treated With Peritoneal Dialysis.
作者信息
Lidgard Benjamin, Shen Jenny I
机构信息
Department of Medicine, University of Washington, Seattle, Washington.
Harbor-UCLA Medical Center, Torrance, California.
出版信息
Kidney Med. 2023 Jul 20;5(8):100699. doi: 10.1016/j.xkme.2023.100699. eCollection 2023 Aug.
Abstract
摘要
相似文献
1
Apixaban Dosing in Patients With Kidney Failure Treated With Peritoneal Dialysis.接受腹膜透析治疗的肾衰竭患者的阿哌沙班给药方案
Kidney Med. 2023 Jul 20;5(8):100699. doi: 10.1016/j.xkme.2023.100699. eCollection 2023 Aug.
2
Apixaban Dosing Patterns Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation Receiving Dialysis: A Retrospective Cohort Study.接受透析治疗的非瓣膜性心房颤动患者的阿哌沙班剂量模式与华法林：一项回顾性队列研究。
Am J Kidney Dis. 2022 Nov;80(5):569-579.e1. doi: 10.1053/j.ajkd.2022.03.007. Epub 2022 Apr 22.
3
Safety and Efficacy of Apixaban Use in Peritoneal Dialysis: A Review of the Literature.阿哌沙班用于腹膜透析的安全性和有效性：文献综述
J Pharm Technol. 2021 Jun;37(3):147-151. doi: 10.1177/8755122520988728. Epub 2021 Jan 20.
4
Single- and multiple-dose pharmacokinetics of a low-dose oral contraceptive in women with chronic renal failure undergoing peritoneal dialysis.低剂量口服避孕药在接受腹膜透析的慢性肾衰竭女性中的单剂量和多剂量药代动力学。
Am J Obstet Gynecol. 1993 May;168(5):1400-6. doi: 10.1016/s0002-9378(11)90772-8.
5
Vancomycin in peritoneal dialysis: Clinical pharmacology considerations in therapy.万古霉素在腹膜透析中的应用：治疗中的临床药理学考虑。
Perit Dial Int. 2020 Jul;40(4):384-393. doi: 10.1177/0896860819889774. Epub 2020 Feb 17.
6
Effect of peritoneal dialysis in end-stage renal disease on apixaban pharmacokinetics.腹膜透析治疗终末期肾病对阿哌沙班药代动力学的影响。
Nephrol Dial Transplant. 2023 Jul 31;38(8):1918-1920. doi: 10.1093/ndt/gfad087.
7
Apixaban versus No Anticoagulation in Patients Undergoing Long-Term Dialysis with Incident Atrial Fibrillation.行长期血液透析且新发心房颤动患者中应用阿哌沙班与不抗凝治疗的比较。
Clin J Am Soc Nephrol. 2020 Aug 7;15(8):1146-1154. doi: 10.2215/CJN.11650919. Epub 2020 May 22.
8
Comparison of the Safety and Effectiveness of Apixaban versus Warfarin in Patients with Severe Renal Impairment.阿哌沙班与华法林在重度肾功能损害患者中的安全性和有效性比较。
Pharmacotherapy. 2017 Apr;37(4):412-419. doi: 10.1002/phar.1905. Epub 2017 Mar 10.
9
Apixaban in patients on haemodialysis: a single-dose pharmacokinetics study.阿哌沙班在血液透析患者中的单次药代动力学研究。
Nephrol Dial Transplant. 2021 Apr 26;36(5):884-889. doi: 10.1093/ndt/gfaa351.
10
A comparison of transplant outcomes in peritoneal and hemodialysis patients.腹膜透析和血液透析患者移植结局的比较。
Kidney Int. 2002 Oct;62(4):1423-30. doi: 10.1111/j.1523-1755.2002.kid563.x.
引用本文的文献
1
Apixaban removal during emergency surgery for type A acute aortic dissection: a prospective cohort study.A型急性主动脉夹层急诊手术期间阿哌沙班的清除：一项前瞻性队列研究。
Int J Surg. 2024 Dec 1;110(12):7782-7790. doi: 10.1097/JS9.0000000000002137.
2
Safety and efficacy of apixaban versus warfarin in peritoneal dialysis patients with non-valvular atrial fibrillation: protocol for a prospective, randomised, open-label, blinded endpoint trial (APIDP2).比较非瓣膜性心房颤动腹膜透析患者应用阿哌沙班和华法林的安全性和有效性的前瞻性、随机、开放标签、盲终点试验（APIDP2）方案。
BMJ Open. 2024 Sep 20;14(9):e089353. doi: 10.1136/bmjopen-2024-089353.
本文引用的文献
1
Pharmacokinetics of Apixaban Among Peritoneal Dialysis Patients.腹膜透析患者中阿哌沙班的药代动力学
Kidney Med. 2023 May 2;5(8):100646. doi: 10.1016/j.xkme.2023.100646. eCollection 2023 Aug.
2
Effect of peritoneal dialysis in end-stage renal disease on apixaban pharmacokinetics.腹膜透析治疗终末期肾病对阿哌沙班药代动力学的影响。
Nephrol Dial Transplant. 2023 Jul 31;38(8):1918-1920. doi: 10.1093/ndt/gfad087.
3
Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial.阿哌沙班用于血液透析的心房颤动患者：一项多中心随机对照试验。
Circulation. 2022 Dec 6;146(23):1735-1745. doi: 10.1161/CIRCULATIONAHA.121.054990. Epub 2022 Nov 6.
4
Apixaban in patients on haemodialysis: a single-dose pharmacokinetics study.阿哌沙班在血液透析患者中的单次药代动力学研究。
Nephrol Dial Transplant. 2021 Apr 26;36(5):884-889. doi: 10.1093/ndt/gfaa351.
5
Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation.非瓣膜性心房颤动患者阿哌沙班的群体药代动力学。
CPT Pharmacometrics Syst Pharmacol. 2018 Nov;7(11):728-738. doi: 10.1002/psp4.12347. Epub 2018 Sep 30.
6
Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients.血液透析患者阿哌沙班稳态时的药代动力学
J Am Soc Nephrol. 2017 Jul;28(7):2241-2248. doi: 10.1681/ASN.2016090980. Epub 2017 Mar 16.
7
Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa.利福平对阿哌沙班（一种口服Xa因子直接抑制剂）药代动力学的影响。
Am J Cardiovasc Drugs. 2016 Apr;16(2):119-27. doi: 10.1007/s40256-015-0157-9.
8
Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis.阿哌沙班在接受血液透析的终末期肾病患者中的药代动力学、药效学及安全性
J Clin Pharmacol. 2016 May;56(5):628-36. doi: 10.1002/jcph.628. Epub 2015 Dec 22.
9
Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects.体重极端变化对健康受试者中阿哌沙班的药代动力学、药效学、安全性和耐受性的影响。
Br J Clin Pharmacol. 2013 Dec;76(6):908-16. doi: 10.1111/bcp.12114.
10
Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects.健康受试者多次口服Xa因子抑制剂阿哌沙班的安全性、药代动力学和药效学
Br J Clin Pharmacol. 2013 Nov;76(5):776-86. doi: 10.1111/bcp.12106.
Zotero 插件